- Home
- BRDG vs VERV Comparison
BRDG vs VERV Comparison
Compare BRDG & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRDG
- VERV
- Stock Information
- Founded
- BRDG 2009
- VERV 2018
- Country
- BRDG United States
- VERV United States
- Employees
- BRDG N/A
- VERV N/A
- Industry
- BRDG Investment Managers
- VERV Medicinal Chemicals and Botanical Products
- Sector
- BRDG Finance
- VERV Health Care
- Exchange
- BRDG Nasdaq
- VERV Nasdaq
- Market Cap
- BRDG 391.6M
- VERV 384.2M
- IPO Year
- BRDG 2021
- VERV 2021
- Fundamental
- Price
- BRDG $9.72
- VERV $11.21
- Analyst Decision
- BRDG Hold
- VERV Buy
- Analyst Count
- BRDG 5
- VERV 9
- Target Price
- BRDG $11.30
- VERV $14.75
- AVG Volume (30 Days)
- BRDG 369.2K
- VERV 8.0M
- Earning Date
- BRDG 08-05-2025
- VERV 08-07-2025
- Dividend Yield
- BRDG 4.35%
- VERV N/A
- EPS Growth
- BRDG N/A
- VERV N/A
- EPS
- BRDG N/A
- VERV N/A
- Revenue
- BRDG $453,729,000.00
- VERV $59,613,000.00
- Revenue This Year
- BRDG N/A
- VERV $27.75
- Revenue Next Year
- BRDG $36.21
- VERV N/A
- P/E Ratio
- BRDG N/A
- VERV N/A
- Revenue Growth
- BRDG 39.05
- VERV 271.44
- 52 Week Low
- BRDG $6.96
- VERV $2.87
- 52 Week High
- BRDG $11.69
- VERV $11.41
- Technical
- Relative Strength Index (RSI)
- BRDG 56.18
- VERV 85.11
- Support Level
- BRDG $9.11
- VERV $11.04
- Resistance Level
- BRDG $9.93
- VERV $11.41
- Average True Range (ATR)
- BRDG 0.23
- VERV 0.40
- MACD
- BRDG 0.03
- VERV 0.53
- Stochastic Oscillator
- BRDG 74.40
- VERV 96.87
About BRDG Bridge Investment Group Holdings Inc.
Bridge Investment Group Holdings Inc is a vertically integrated investment manager, diversified across specialized asset classes. The company combines its operating platform with dedicated teams of investment professionals focused on various specialized and synergistic investment platforms, including real estate, credit, renewable energy, and secondaries strategies. Its products and vertically integrated structure allow it to capture new market opportunities and serve investors with various investment objectives. The Company operates as one business, a fully integrated real estate investment manager.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.